Compare TG Therapeutics Inc (TGTX) vs US Foods Holding Corp. Common Stock (USFD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs US Foods Holding Corp. Common Stock — how do they compare? TG Therapeutics Inc trades at $53.34 (market cap $8.11B), while US Foods Holding Corp. Common Stock trades at $97.36 (market cap $20.78B). The key difference: US Foods Holding Corp. Common Stock is far larger — about 2.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, US Foods Holding Corp. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 15 Days and US Foods Holding Corp. Common Stock for 0 Days on average.
| TGTX | USFD | |
|---|---|---|
Market Cap | $8.11B | $20.78B |
Volume | 1,505,658 | 1,109,124 |
Sector | Health | Industrials |
52-Week High | $59.06 | $110.94 |
52-Week Low | $26.94 | $70.05 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $8.31B | $26.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About US Foods Holding Corp. Common Stock
US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →
